203 related articles for article (PubMed ID: 34941096)
1. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
[TBL] [Abstract][Full Text] [Related]
2. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
3. Teriflunomide-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.
Khurana D; Kaur G; Sendhil Kumaran M; Choudhary R; Ashraf R; Thakur V
Clin Exp Dermatol; 2021 Jan; 46(1):166-169. PubMed ID: 32557734
[No Abstract] [Full Text] [Related]
4. Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases.
Krajnc N; Brecl Jakob G; Gomezelj S; Šega Jazbec S
Clin Neurol Neurosurg; 2021 Jul; 206():106685. PubMed ID: 34020325
[TBL] [Abstract][Full Text] [Related]
5. Teriflunomide, a potential novel cause of chronic active colitis.
Kővári B; Zachs J; Murchie B; Lauwers GY
Histopathology; 2020 Dec; 77(6):1000-1001. PubMed ID: 32323888
[No Abstract] [Full Text] [Related]
6. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
7. An updated review of teriflunomide's use in multiple sclerosis.
Miller AE
Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
[TBL] [Abstract][Full Text] [Related]
9. Teriflunomide-associated urolithiasis: a new adverse reaction explained by its uricosuric effect.
Largeau B; Béra F; Vannier J; Jonville-Béra AP
Fundam Clin Pharmacol; 2021 Oct; 35(5):930-932. PubMed ID: 33458875
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study.
Qiu W; Huang DH; Hou SF; Zhang MN; Jin T; Dong HQ; Peng H; Zhang CD; Zhao G; Huang YN; Zhou D; Wu WP; Wang BJ; Li JM; Zhang XH; Cheng Y; Li HF; Li L; Lu CZ; Zhang X; Bu BT; Dong WL; Fan DS; Hu XQ; Xu XH;
Chin Med J (Engl); 2018 Dec; 131(23):2776-2784. PubMed ID: 30511679
[TBL] [Abstract][Full Text] [Related]
11. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
[TBL] [Abstract][Full Text] [Related]
12. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
13. ▼Teriflunomide for multiple sclerosis.
Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
[TBL] [Abstract][Full Text] [Related]
14. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK
J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149
[No Abstract] [Full Text] [Related]
16. Teeth loss after teriflunomide treatment: Casual or causal? A short case series.
Vacchiano V; Frattaruolo N; Mancinelli L; Foschi M; Carotenuto A; Scandellari C; Piattelli M; Brescia Morra V; Lugaresi A
Mult Scler Relat Disord; 2018 Aug; 24():120-122. PubMed ID: 29982109
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
Vukusic S; Coyle PK; Jurgensen S; Truffinet P; Benamor M; Afsar S; Purvis A; Poole EM; Chambers C
Mult Scler; 2020 Jun; 26(7):829-836. PubMed ID: 30968734
[TBL] [Abstract][Full Text] [Related]
18. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
Miller AE
Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
[TBL] [Abstract][Full Text] [Related]
19. Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
Son M; McEwan L; Ubaidat M; Bovell K; Morrow SA
Mult Scler; 2020 Nov; 26(13):1801-1803. PubMed ID: 32031458
[TBL] [Abstract][Full Text] [Related]
20. Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.
Fischer-Barnicol B; Oechtering J; Kuhle J; Lorscheider J; Kappos L; Derfuss T
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
